Liver Cancer Drug Global Market Report 2025

The liver cancer drug market size has grown rapidly in recent years. It will grow from $2.34 billion in 2024 to $2.64 billion in 2025 at a compound annual growth rate (CAGR) of 12.7%. The growth observed during the historic period can be credited to the rising incidence of liver cancer, an increasing aging population, expanding global healthcare expenditure, heightened awareness and screening efforts, and a growing demand for immunotherapy.

The liver cancer drug market size is expected to see rapid growth in the next few years. It will grow to $4.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The anticipated growth in the forecast period can be attributed to increased investments in clinical trials, a rising adoption of precision medicine, a surge in global drug approvals, a growing prevalence of hepatitis, and expanding research and innovation. Key trends expected during the forecast period include progress in targeted therapies, advancements in immunotherapy treatments, developments in personalized medicine, the integration of artificial intelligence in oncology, and the incorporation of biomarker diagnostics.

The growing investment in research and development is expected to drive the expansion of the liver cancer drug market. Research and development involve a systematic process of investigating, designing, and assessing new products, technologies, or techniques to enhance knowledge and deliver innovative solutions to the market. The increase in research and development is driven by a rising demand for innovation and technological progress across industries, prompting companies to develop new products and improve existing ones to remain competitive. In the context of liver cancer drugs, research and development support the discovery of targeted therapies that enhance treatment efficacy while minimizing harm to healthy liver tissue. For example, in September 2024, Cancer Research UK, a UK-based cancer research organization, reported an investment of $533 million (£399 million) in cancer research during the 2023/24 financial year, with $124 million (£93 million) allocated to research relevant to all cancer types and $112 million (£84 million) directed to fundamental biological studies. Therefore, the increase in research and development activities is contributing to the growth of the liver cancer drug market.

Key players in the liver cancer drug market are prioritizing the development of innovative treatments, including advanced therapies, to improve treatment accuracy and patient outcomes. Advanced liver cancer therapies encompass novel approaches such as immunotherapy, targeted therapy, gene therapy, CAR-T cell therapy, and minimally invasive techniques such as TACE and ablation, which aim to increase the effectiveness and precision of liver cancer treatment. For instance, in November 2023, Terumo India, an India-based medical device manufacturer, launched advanced Balloon-TACE therapy for liver cancer in India, featuring two innovative devices, Occlusafe and LifePearl. These devices are designed to enhance the accuracy and efficiency of transcatheter arterial chemoembolization (TACE) by delivering chemotherapy directly to liver tumors while limiting damage to healthy tissue and maintaining liver function, specifically targeting hepatocellular carcinoma, the most prevalent form of liver cancer in India.

In September 2023, Coherus BioSciences Inc., a US-based biopharmaceutical firm, completed the acquisition of Surface Oncology Inc. for an undisclosed amount. Through this acquisition, Coherus expanded its immuno-oncology pipeline to include several antibody-based immunotherapy candidates. These treatments are intended to enhance both innate and adaptive immune system responses, ultimately improving therapeutic outcomes for cancer patients. Surface Oncology Inc. is a US-based company specializing in the development of liver cancer drugs.

Major players in the liver cancer drug market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company Limited, Hetero Drugs Limited, Sun pharma, Eisai Company Limited, Genentech Incorporated, Ipsen Société Anonyme, Cipla Limited, Dr. Reddy’s Laboratories Limited, BeiGene Ltd., Exelixis Incorporated, Natco Pharma Limited, and MacroGenics Inc.

North America was the largest region in the liver cancer drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the liver cancer drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liver cancer drugs are a category of pharmaceutical substances formulated to address the growth of malignant cells in a critical organ responsible for detoxification, metabolism, and nutrient storage. These medications function by interfering with the biological processes that support the proliferation, division, and immune evasion of abnormal cells.

The primary categories of liver cancer drugs include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and others. Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancer, indicating it originates within the liver rather than metastasizing from another organ. Treatment options encompass targeted therapy, immunotherapy, chemotherapy, and others, which may be administered orally or via injection. These drugs are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online platforms.

The liver cancer drugs market research report is one of a series of new reports that provides liver cancer drugs market statistics, including liver cancer drugs industry global market size, regional shares, competitors with a liver cancer drugs market share, detailed liver cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer drugs industry. This liver cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liver cancer drug market consists of revenues earned by entities by providing services such as clinical trial management, pharmacovigilance services, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer drug market also includes sales of monoclonal antibodies, hormonal therapy drugs, gene therapy products, and liver-specific drug delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.